167 related articles for article (PubMed ID: 35029914)
1. Diagnostic method for malignant pleural effusion distinguishing malignant mesothelioma from lung cancer using pleural carcinoembryonic antigen and hyaluronic acid levels.
Saraya T; Ohkuma K; Fujiwara M; Ishii H
Medicine (Baltimore); 2022 Jan; 101(1):e28517. PubMed ID: 35029914
[TBL] [Abstract][Full Text] [Related]
2. A novel diagnostic method for distinguishing parapneumonic effusion and empyema from other diseases by using the pleural lactate dehydrogenase to adenosine deaminase ratio and carcinoembryonic antigen levels.
Saraya T; Ohkuma K; Koide T; Goto H; Takizawa H; Light RW
Medicine (Baltimore); 2019 Mar; 98(13):e15003. PubMed ID: 30921217
[TBL] [Abstract][Full Text] [Related]
3. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies.
Fuhrman C; Duche JC; Chouaid C; Abd Alsamad I; Atassi K; Monnet I; Tillement JP; Housset B
Clin Biochem; 2000 Jul; 33(5):405-10. PubMed ID: 11018693
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis.
Shi HZ; Liang QL; Jiang J; Qin XJ; Yang HB
Respirology; 2008 Jun; 13(4):518-27. PubMed ID: 18422869
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
[TBL] [Abstract][Full Text] [Related]
6. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma.
Atagi S; Ogawara M; Kawahara M; Sakatani M; Furuse K; Ueda E; Yamamoto S
Jpn J Clin Oncol; 1997 Oct; 27(5):293-7. PubMed ID: 9390204
[TBL] [Abstract][Full Text] [Related]
7. [The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].
Wei F; Wei Y; Li LF; Li GL; Wang GJ
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):524-527. PubMed ID: 28728299
[No Abstract] [Full Text] [Related]
8. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
Creaney J; Dick IM; Segal A; Musk AW; Robinson BW
Lung Cancer; 2013 Dec; 82(3):491-8. PubMed ID: 24161718
[TBL] [Abstract][Full Text] [Related]
9. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of soluble B7-H4 and carcinoembryonic antigen in distinguishing malignant from benign pleural effusion.
Jing X; Wei F; Li J; Dai L; Wang X; Jia L; Wang H; An L; Yang Y; Zhang G; Cheng Z
Clin Respir J; 2018 Mar; 12(3):986-990. PubMed ID: 28127951
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic value of CEA for lung cancer-related malignant pleural effusion in China: a meta-analysis.
Cheng C; Yang Y; Yang W; Wang D; Yao C
Expert Rev Respir Med; 2022 Jan; 16(1):99-108. PubMed ID: 34112035
[TBL] [Abstract][Full Text] [Related]
13. CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause.
Wang XF; Wu YH; Wang MS; Wang YS
Asian Pac J Cancer Prev; 2014; 15(1):363-8. PubMed ID: 24528057
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma.
Fujimoto N; Gemba K; Asano M; Fuchimoto Y; Wada S; Ono K; Ozaki S; Kishimoto T
Respir Investig; 2013 Jun; 51(2):92-7. PubMed ID: 23790737
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic potential of carcinoembryonic antigen and ferritine in tuberculous and malignant pleural effusion.
Loncar R; Ostojic L; Tabakovic-Loncar V; Roguljić A
Tumori; 1995; 81(6):440-4. PubMed ID: 8804473
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
Dong J; Sun G; Zhu H
Tumour Biol; 2016 Mar; 37(3):3257-64. PubMed ID: 26438059
[TBL] [Abstract][Full Text] [Related]
17. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of the cancer ratio for the prediction of malignant pleural effusion: evidence from a validation study and meta-analysis.
Zhang Y; Li X; Liu J; Hu X; Wan C; Zhang R; Shen Y
Ann Med; 2021 Dec; 53(1):558-566. PubMed ID: 33818231
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion.
Lai RS; Chen CC; Lee PC; Lu JY
Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study.
Fan X; Liu Y; Liang Z; Wang S; Yang J; Wu A
Pathol Oncol Res; 2022; 28():1610280. PubMed ID: 35515016
[No Abstract] [Full Text] [Related]
[Next] [New Search]
